MedTrace Logo

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases.

II. Determine the kinetics of T- and B-cell immune reconstitution after a combination of timed plasmapheresis, high dose cyclophosphamide and total lymphoid irradiation, and posttransplant immunosuppression with cyclosporine in these patients.

III. Determine whether this treatment regimen beneficially influences the clinical course of these patients.

Conditions

Interventions

DRUG

anti-thymocyte globulin

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

filgrastim

DRUG

methylprednisolone

DRUG

prednisone

PROCEDURE

Autologous Peripheral Blood Stem Cell Transplantation

Sponsors & Collaborators

  • Fairview University Medical Center

    lead OTHER

Principal Investigators

  • Arne Slungaard · Fairview University Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
1 Year
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006055 on ClinicalTrials.gov